保集健康年度报告2025

(Incorporated in the Cayman Islands with limited liability) Stock Code1246 ANNUAL REPORT 目錄Contents 2CORPORATE INFORMATION 5CHAIRMAN’S STATEMENT 100DIRECTORS’ REPORT 7MANAGEMENT DISCUSSION ANDANALYSIS 117INDEPENDENT AUDITOR’S REPORT 29BIOGRAPHICAL DETAILS OFDIRECTORS AND SENIORMANAGEMENT 121CONSOLIDATED STATEMENT OF PROFITOR LOSS AND OTHER COMPREHENSIVEINCOME 33ENVIRONMENTAL, SOCIAL ANDGOVERNANCE REPORT 123CONSOLIDATED STATEMENT OFFINANCIAL POSITION 72CORPORATE GOVERNANCE REPORT 125CONSOLIDATED STATEMENT OFCHANGES IN EQUITY 127CONSOLIDATED STATEMENT OF CASHFLOWS 129NOTES TO THE CONSOLIDATEDFINANCIAL STATEMENTS 248FIVE YEARS FINANCIAL SUMMARY 公司資料Corporate Information BOARD OF DIRECTORS Executive Directors Mr. Yu Jinlong(Chairman) (appointed on 10 March 2025) Mr. He Yu (appointed on 30 December 2024)Mr. Qiu Dongfang (resigned on 30 December 2024)Mr. Zhang Shenghai (removed on 19 February 2025) Non-Executive Directors Dr. Tang Sing Hing, Kenny (appointed on 30 December 2024)Mr. Chui Kwong Kau (resigned on 30 December 2024) Independent Non-Executive Directors Ms. Mak Suet Man (appointed on 30 December 2024)Mr. Chan Chi Hang (appointed on 30 December 2024)Mr. Liang Yanan (appointed on 30 December 2024)Mr. Wang Zhe (removed on 19 February 2025)Ms. Tang Man Yi (resigned on 27 July 2024)Mr. Yi Baxian (resigned on 30 December 2024) BOARD COMMITTEES Audit Committee Ms. Mak Suet Man(Chairman) (appointed on 30 December 2024) Mr. Chan Chi Hang (appointed on 30 December 2024)Mr. Liang Yanan (appointed on 30 December 2024)Ms. Tang Man Yi (resigned on 27 July 2024)Mr. Yi Baxian (resigned on 30 December 2024)Mr. Wang Zhe (removed on 19 February 2025) Nomination Committee Mr. Liang Yanan(Chairman) (appointed on 30 December 2024) Ms. Mak Suet Man (appointed on 30 December 2024)Mr. Chan Chi Hang (appointed on 30 December 2024)Mr. Yi Baxian (resigned on 30 December 2024)Mr. Wang Zhe (removed on 19 February 2025) 公司資料Corporate Information Remuneration Committee Mr. Chan Chi Hang(Chairman) (appointed on 30 December 2024) Mr. Liang Yanan (appointed on 30 December 2024)Ms. Mak Suet Man (appointed on 30 December 2024)Ms. Tang Man Yi (resigned on 27 July 2024)Mr. Yi Baxian (resigned on 30 December 2024)Mr. Wang Zhe (removed on 19 February 2025) COMPANY SECRETARY Mr. Hui Hung Kwan (appointed on 30 December 2024)Mr. Yuen Wai Keung (removed on 23 July 2024) AUTHORISED REPRESENTATIVES Mr. He Yu (appointed on 30 December 2024)Mr. Hui Hung Kwan (appointed on 30 December 2024)Mr. Yuen Wai Keung (appointed on 2 May 2024 and removed on23 July 2024)Mr. Qiu Dongfang (resigned on 30 December 2024)Mr. Ng Kam Ming (resigned on 2 May 2024) REGISTERED OFFICE Windward 3,Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands Windward 3,Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands AUDITOR 255151501 Infinity CPA LimitedCertified Public AccountantsRoom 1501, 15/F, Olympia Plaza255 King’s RoadNorth PointHong Kong LEGAL ADVISER 1817 Reed Smith Richards Butler LLP17/F One Island East18 Westlands RoadQuarry Bay, Hong Kong 公司資料Corporate Information HEAD OFFICE AND PRINCIPAL PLACE OFBUSINESS IN HONG KONG 167-16915 15/F, Toi Shan Association Building167-169 Hennessy RoadWan ChaiHong Kong PRINCIPAL SHARE REGISTRAR AND TRANSFEROFFICE Ocorian Trust (Cayman) LimitedWindward 3,Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands Ocorian Trust (Cayman) LimitedWindward 3,Regatta Office ParkPO Box 1350Grand Cayman KY1-1108Cayman Islands HONG KONG BRANCH SHARE REGISTRAR ANDTRANSFER OFFICE 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong PRINCIPAL BANKERS Bank of China (Hong Kong) LimitedCMB Wing Lung Bank Limited STOCK CODE 1246 1246 (Main Board of The Stock Exchange of Hong Kong Limited) WEBSITE www.boillhealthcare.com.hk www.boillhealthcare.com.hk 主席報告書Chairman’s Statement Dear Shareholders, On behalf of the board (“Board”) of directors (“Director(s)”) of BoillHealthcare Holdings Limited (“Company”) and its subsidiaries (collectivelythe “Group”), I am pleased to present the annual auditedconsolidated results of the Group for the financial year ended 31March 2025 (“FY2025”) to the shareholders of the Company (the“Shareholders”). 76.9285.2208.373.0%43.2285.033.5 The Group’s revenue for FY2025 was approximately HK$76.9million, representing a decrease of approximately HK$208.3 millionor 73.0% from approximately HK$285.2 million for the year ended31 March 2024 (“FY2024”). The revenue from the propertydevelopment and sales of construction materials for FY2025 wereapproximately HK$43.2 million (FY2024: approximately HK$285.0m i l l i o n ) a n d a p p r o x i m a t e l y H K $ 3 3 . 5 m i l l i o n ( F Y 2 0 2 4 : n i l )respectively. The Group has resumed the business of sales ofconstruction materials during FY2025 to increase its revenuestreams. 830.0118.661.128.74190.536.6449.218.8 The loss attributable to owne